Borosil Scientific Ltd
NSE: BOROSCI BSE: 544184Pharma
Since 1962, Borosil is into finest quality scientific and laboratory glassware, which is used in Quality Control in pharmaceutical industries, Food and Soil testing, Microbiology, and Biotechnology.[1]
₹117
52W: ₹96.6 — ₹191
PE 25.9 · Book ₹48.3 · +142% vs bookMarket Cap₹1,041 Cr
Stock P/E25.9Price to Earnings
ROCE12%Return on Capital
ROE8.75%Return on Equity
Div. Yield0%Face Value ₹1
Strengths
- +Company has reduced debt.
- +Company is almost debt free.
- +Company's working capital requirements have reduced from 156 days to 95.6 days
Weaknesses
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has a low return on equity of 8.67% over last 3 years.
Shareholding Pattern
Promoters68.08%
FIIs0.09%
DIIs0.26%
Public31.57%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 67.92% | 67.86%▼0.1 | 67.84%▼0.0 | 67.81%▼0.0 | 67.8%▼0.0 | 67.8% | 67.8% | 68.08%▲0.3 |
| FIIs | 0.38% | 0.37%▼0.0 | 0.27%▼0.1 | 0.24%▼0.0 | 0.2%▼0.0 | 0.07%▼0.1 | 0.07% | 0.09%▲0.0 |
| DIIs | 0.15% | 0.01%▼0.1 | 0.02%▲0.0 | 0.02% | 0.05%▲0.0 | 0.1%▲0.1 | 0.19%▲0.1 | 0.26%▲0.1 |
| Public | 31.54% | 31.74%▲0.2 | 31.88%▲0.1 | 31.91%▲0.0 | 31.93%▲0.0 | 32.03%▲0.1 | 31.93%▼0.1 | 31.57%▼0.4 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 84 | 88 | 103 | 93 | 87 | 94 | 118 | 89 | 99 | 107 |
| Expenses | 72 | 75 | 84 | 82 | 74 | 82 | 96 | 80 | 87 | 89 |
| Operating Profit | 12 | 13 | 19 | 11 | 14 | 12 | 21 | 9 | 12 | 18 |
| OPM % | 15% | 15% | 18% | 12% | 16% | 13% | 18% | 10% | 12% | 17% |
| Net Profit | 8 | 7 | 12 | 6 | 8 | 7 | 14 | 0 | 8 | 10 |
| EPS ₹ | 0 | 0.84 | 1.36 | 0.73 | 0.87 | 0.75 | 1.59 | 0.05 | 0.85 | 1.15 |
AI Insights
Revenue Trend
TTM revenue at ₹413Cr, up 6.2% YoY. OPM at 15%.
Debt Position
Borrowings at ₹2Cr. Debt-to-equity ratio: 0.00x. Healthy balance sheet.
Capex Cycle
CWIP at ₹2Cr (1% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 0.26% (+0.11pp change). FIIs: 0.09% (-0.29pp change). Promoters hold 68.08%.
Margin & Efficiency
ROCE improving from 0% (Mar 2023) to 12% (Mar 2025). Working capital days: 96.
Valuation
PE 25.9x with 12% ROCE. Price is 142% above book value of ₹48.3. Dividend yield: 0%.
Recent Announcements
- Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter & Year Ended March 31, 2026 And Consider Seeking Approval Of Shareholders (Through Enabling Resolution) For Raising Funds Through Various Modes. 13 May - Board meets May 20, 2026 to approve FY26 results and seek fundraising approval via QIP/FPO/FCB.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 3 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and participants) Regulations, 2018 for the Quarter ended March 31, 2026
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 1 Apr - Shreevar Kheruka bought 4,15,426 shares (0.47%) from Mar 9–30, 2026; promoter holding now 68.27%.
- Closure of Trading Window 26 Mar
- Announcement under Regulation 30 (LODR)-Investor Presentation 13 Feb - Investor presentation for unaudited financial results for quarter and nine months ended December 31, 2025
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Rating update 9 Dec 2025 from care